Male pattern hair loss, or androgenetic alopecia, is the most common cause of hair loss in men, affecting around half of all men over 50 — though it can begin as early as the late teens. Driven by a combination of genetic predisposition and the hormone dihydrotestosterone (DHT), it follows a characteristic pattern of temple recession and crown thinning. Whilst not medically dangerous, it can significantly affect self-esteem and quality of life. This article explains the causes, stages, and evidence-based treatments available in the UK, including licensed medicines and surgical options, and advises when to seek professional assessment.

What Is Male Pattern Hair Loss and Who Does It Affect?

Male pattern hair loss (androgenetic alopecia) is the most common form of hair loss in men, affecting around 50% of men over 50 and driven by genetic and hormonal factors. Diagnosis is usually clinical and does not typically require investigation.

Not sure if this is normal? Chat with one of our pharmacists →

Male pattern hair loss, known medically as androgenetic alopecia, is the most common form of hair loss in men. It is a progressive condition characterised by a predictable pattern of thinning and recession, driven primarily by genetic and hormonal factors. Far from being a rare condition, it affects a significant proportion of the male population — estimates suggest that approximately 50% of men over the age of 50 experience some degree of androgenetic alopecia, though it can begin as early as the late teens or early twenties.

The condition is not limited to any particular ethnic group, though prevalence does vary across populations. Men with a family history of hair loss — on either the maternal or paternal side — carry a notably higher risk of developing the condition themselves. Whilst male pattern hair loss is not medically dangerous, it can have a considerable psychological impact, affecting self-esteem, body image, and overall quality of life; this aspect deserves the same attention as any physical symptom.

In most cases, the diagnosis of male pattern hair loss is clinical — based on the characteristic pattern and history — and does not require investigation. It is important, however, to distinguish it from other forms of alopecia, such as alopecia areata (an autoimmune condition causing patchy loss) or telogen effluvium (diffuse shedding often triggered by stress or illness). If features are atypical, professional assessment is recommended. Reliable information is available from the NHS, the British Association of Dermatologists (BAD), and the Primary Care Dermatology Society (PCDS).

Recognising the Signs and Stages of Hair Loss

Male pattern hair loss typically begins with temple recession forming an 'M' shape or thinning at the crown, classified using the Norwood–Hamilton Scale (Types I–VII). Sudden, patchy, or scarring hair loss is not typical and requires prompt medical review.

The earliest signs of male pattern hair loss are often subtle and may go unnoticed for some time. Typically, the process begins with a gradual recession of the hairline at the temples, creating an 'M'-shaped pattern, or with thinning at the crown (vertex) of the scalp. In some men, both areas are affected simultaneously. Hair in the affected regions tends to become finer, shorter, and lighter in colour before eventually ceasing to grow altogether.

The Norwood–Hamilton Scale is the most widely used classification system for staging male pattern hair loss. It ranges from Type I (minimal recession) through to Type VII (extensive loss leaving only a horseshoe-shaped band of hair around the sides and back of the scalp). Identifying where on this scale a person sits can help guide treatment decisions and set realistic expectations about outcomes.

The rate of progression varies considerably between individuals. Some men experience rapid, significant loss over a few years, whilst others see only slow, gradual changes over decades. Keeping a photographic record over time can be a useful way to monitor progression objectively. Where available, dermoscopy or trichoscopy can assist clinicians in confirming follicular miniaturisation, particularly in less clear-cut cases.

If hair loss appears sudden, patchy, or is accompanied by scalp inflammation, redness, scaling, pustules, pain, or any suggestion of scarring, these features are not typical of androgenetic alopecia. Scarring alopecias and conditions such as tinea capitis (scalp ringworm) require prompt medical review and, where scarring is suspected, urgent referral to a dermatologist, as irreversible follicular damage may occur if treatment is delayed.

Causes and Risk Factors Explained

Male pattern hair loss is caused by DHT acting on genetically susceptible scalp follicles, causing progressive follicular miniaturisation. Genetics from both parents are relevant; nutritional deficiencies and stress do not cause androgenetic alopecia but may worsen concurrent shedding.

The underlying cause of male pattern hair loss is a combination of genetic predisposition and the action of androgens — specifically dihydrotestosterone (DHT). DHT is a potent derivative of testosterone, produced through the action of the enzyme 5-alpha reductase. In genetically susceptible individuals, hair follicles on the scalp contain androgen receptors that are particularly sensitive to DHT. Prolonged exposure causes these follicles to miniaturise — a process whereby the growth phase (anagen) of the hair cycle shortens progressively, resulting in finer, shorter hairs until the follicle eventually becomes dormant.

Genetics play a central role, and the condition is polygenic, meaning multiple genes contribute to susceptibility. Contrary to the popular belief that hair loss is inherited solely from the maternal grandfather, genes from both parents are relevant. Having a first-degree relative with significant hair loss meaningfully increases an individual's own risk.

Whilst androgens and genetics are the primary drivers, several other factors may influence the severity or timing of hair loss:

• Age: Risk increases progressively with age.

• Hormonal changes: Conditions affecting androgen levels may accelerate loss.

• Nutritional factors: Deficiencies in iron, zinc, or vitamin D do not cause androgenetic alopecia, but may contribute to concurrent hair thinning (for example, through telogen effluvium). Routine blood testing is not required in typical male pattern hair loss; investigations should be considered only when the history or examination suggests an alternative or coexisting diagnosis, such as diffuse shedding or systemic symptoms.

• Stress and illness: These may trigger or worsen concurrent telogen effluvium, compounding the appearance of loss.

There is no established link between wearing hats, frequent shampooing, or poor circulation and the development of male pattern hair loss — these remain common myths without clinical evidence.

Treatment Options Available in the UK

Licensed UK treatments include topical minoxidil (over the counter) and oral finasteride 1 mg (prescription-only); neither permanently reverses hair loss, and benefits cease if treatment is stopped. Surgical options (FUT/FUE) are available privately from CQC-registered, GMC-supervised clinics.

Several evidence-based treatments are available in the UK for male pattern hair loss, ranging from licensed medicines to surgical options. No treatment can permanently reverse androgenetic alopecia; rather, the goal is to slow progression and, in some cases, stimulate partial regrowth.

Licensed medical treatments include:

• Minoxidil (topical): Available over the counter as a solution or foam (2% and 5% concentrations), minoxidil is applied directly to the scalp. It is thought to prolong the anagen (growth) phase and improve follicular blood supply. It is licensed by the MHRA for male pattern hair loss; however, age eligibility varies by product — check the specific product's Summary of Product Characteristics (SmPC) or patient information leaflet, as some formulations are not licensed for use below certain ages. Common adverse effects include scalp irritation and, occasionally, unwanted facial or body hair growth (hypertrichosis). An initial increase in shedding during the first few weeks of use is recognised and does not indicate treatment failure. Visible benefit typically takes 3–6 months of consistent use to become apparent, and any benefit is lost if treatment is stopped.

• Finasteride 1 mg (oral, prescription-only): Finasteride 1 mg once daily is the dose licensed specifically for male pattern hair loss in the UK; the 5 mg tablet is licensed for benign prostatic hyperplasia (BPH) and is not licensed for hair loss. Finasteride works by inhibiting 5-alpha reductase, thereby reducing DHT levels in the scalp. Clinical evidence demonstrates that it slows hair loss and promotes regrowth in a significant proportion of users.

• Important safety information — finasteride: Patients must be counselled about the following before starting treatment, in line with MHRA guidance and the product SmPC:
• Sexual side effects, including reduced libido, erectile dysfunction, and ejaculatory disorders, have been reported. In some men, these effects have persisted after stopping finasteride. The MHRA has reviewed this risk; patients should be informed before treatment begins.
• Finasteride has been associated with reports of depression and suicidal ideation. If you experience low mood, depression, or any thoughts of self-harm or suicide, stop taking finasteride and seek medical help immediately.
• Finasteride is contraindicated in women and children. Pregnant women or those who may become pregnant must avoid handling crushed or broken tablets, as absorption through the skin may harm a male foetus.
• Blood donation: Do not donate blood during treatment with finasteride or for at least one month after the last dose, to prevent inadvertent exposure to a pregnant recipient (per NHS Blood and Transplant guidance).
• Any suspected side effects should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Note: The term 'post-finasteride syndrome' is sometimes used to describe persistent side effects after stopping the medicine. This is not a formally recognised medical diagnosis, but the MHRA and the product SmPC do acknowledge that sexual dysfunction may persist in some men after discontinuation.

Experiencing these side effects? Our pharmacists can help you navigate them →

Off-label options: Oral minoxidil and dutasteride are sometimes used for hair loss but are not licensed for this indication in the UK. If a specialist considers these options, treatment should be initiated by a qualified clinician with full informed consent and appropriate monitoring.

Surgical options: Follicular unit transplantation (FUT) and follicular unit extraction (FUE) are available privately in the UK and can produce natural-looking, lasting results in suitable candidates. These procedures are not available on the NHS for cosmetic hair loss. When considering surgery, choose a clinic registered with the Care Quality Commission (CQC) and ensure the operating surgeon is registered with the General Medical Council (GMC). Verify credentials before proceeding.

Be cautious of unregulated products marketed online or in the media; many lack robust clinical evidence and may not be safe.

When to See a GP or Specialist

See a GP if hair loss is sudden, patchy, accompanied by scalp inflammation or scarring, or associated with systemic symptoms such as fatigue or weight changes. Routine blood tests are not required for typical male pattern hair loss unless an alternative or coexisting cause is suspected.

For many men, male pattern hair loss is a cosmetic concern rather than a medical emergency, and it is entirely reasonable to explore over-the-counter options such as topical minoxidil before seeking a GP appointment. However, there are specific circumstances in which professional assessment is strongly recommended.

Consult your GP if:

• Hair loss is sudden or rapid in onset

• Loss is patchy rather than following the typical androgenetic pattern

• The scalp appears inflamed, scaly, scarred, itchy, or there are pustules or pain — particularly if scarring alopecia or tinea capitis is suspected, as these may require urgent referral

• Hair loss is accompanied by other symptoms such as fatigue, weight changes, or skin changes (which may suggest an underlying thyroid disorder or other systemic condition)

• You are considering finasteride and wish to discuss its suitability, risks, and monitoring

• Hair loss is causing significant psychological distress

In typical male pattern hair loss, routine blood tests are not required. However, if the history or examination suggests an alternative or coexisting cause — such as diffuse shedding, systemic symptoms, or features inconsistent with androgenetic alopecia — a GP may arrange targeted investigations, such as thyroid function tests or a full blood count to exclude iron deficiency anaemia.

If the diagnosis is uncertain or the condition is not responding to standard treatment, referral to a consultant dermatologist is appropriate. Assessment and referral pathways for androgenetic alopecia in primary care are outlined by the Primary Care Dermatology Society (PCDS) and the British Association of Dermatologists (BAD), and the NHS provides patient-facing guidance on its hair loss pages.

Private dermatology clinics and trichologists (hair and scalp specialists) are also accessible options outside the NHS pathway. Note that 'trichologist' is not a legally protected title in the UK. When seeking private specialist input, verify that any doctor is registered with the GMC and that clinics are regulated by the CQC. For trichologists, check membership of a recognised professional body such as the Institute of Trichologists or the Trichological Society.

Living With Male Pattern Hair Loss: Support and Outlook

Male pattern hair loss carries no risk to physical health, but can significantly affect psychological wellbeing, including self-confidence and mood. Evidence-based treatments are most effective when started early, and support is available via the NHS, BAD, and PCDS.

Adjusting to male pattern hair loss can be challenging, particularly for younger men or those who experience rapid progression. Research consistently shows that hair loss can affect psychological wellbeing, contributing to reduced self-confidence, social anxiety, and in some cases, symptoms of depression. Acknowledging these feelings is important, and seeking support — whether through a GP, counsellor, or peer support group — is a valid and constructive step. If distress is significant, your GP can refer you to appropriate mental health services.

For many men, acceptance and adaptation become central to their experience. Practical measures such as adjusting hairstyle, using volumising hair products, or choosing to shave the head entirely are all widely adopted approaches that can restore a sense of control and confidence. There is no single 'right' response to hair loss, and individual preferences should always be respected.

From a medical perspective, male pattern hair loss carries no risk to physical health and is not associated with any serious systemic illness. The hair follicles become miniaturised rather than destroyed, which is why treatments such as minoxidil and finasteride can be effective — particularly when started early, before significant miniaturisation has occurred. The earlier treatment is initiated, the greater the potential to preserve existing hair.

Reliable information and support are available from the NHS (NHS hair loss pages), the British Association of Dermatologists (BAD patient leaflets), and the Primary Care Dermatology Society (PCDS). Men are encouraged to seek evidence-based advice rather than turning to unregulated remedies. If you experience any suspected side effects from a hair loss medicine, report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. Male pattern hair loss — whilst common and sometimes distressing — is a manageable condition with a range of legitimate, evidence-based options available.

Frequently Asked Questions